96 related articles for article (PubMed ID: 19697811)
1. [Concentration of soluble ligand for receptor CD30 (sCD30L)--marker of apoptosis in women with ovarian tumor].
Mielczarek-Palacz A; Kondera-Anasz Z; Sikora J; Sodowski K; Switała J; Kubina R
Ginekol Pol; 2009 Jul; 80(7):494-7. PubMed ID: 19697811
[TBL] [Abstract][Full Text] [Related]
2. Imbalance in serum soluble CD30/CD30L and CD40/CD40L systems are associated with ovarian tumors.
Mielczarek-Palacz A; Sikora J; Kondera-Anasz Z; Hauza G
Hum Immunol; 2013 Jan; 74(1):70-4. PubMed ID: 23073297
[TBL] [Abstract][Full Text] [Related]
3. Cytotoxic reaction mediators: granzymes A and B in women with ovarian cancer.
Mielczarek-Palacz A; Sikora J; Kondera-Anasz Z; Bednarek I
Tissue Antigens; 2014 Jun; 83(6):409-13. PubMed ID: 24673566
[TBL] [Abstract][Full Text] [Related]
4. [Metabolic activity of peripheral blood neutrophils in women with ovarian tumours].
Kondera-Anasz Z; Mielczarek-Palacz A; Switała J; Piasecka A
Ginekol Pol; 2004 Aug; 75(8):609-14. PubMed ID: 15517784
[TBL] [Abstract][Full Text] [Related]
5. Myeloid and lymphoid dendritic cells in the peritoneal fluid of women with ovarian cancer.
Wertel F; Polak G; Roliński J; Barczyński B; Kotarski J
Adv Med Sci; 2006; 51():174-7. PubMed ID: 17357302
[TBL] [Abstract][Full Text] [Related]
6. [Changes in calprotectin concentration--inflammation marker in serum of women with gynecological cancer].
Mielczarek-Palacz A; Sikora J; Kondera-Anasz Z; Nocoń M
Ginekol Pol; 2011 Nov; 82(11):822-6. PubMed ID: 22384614
[TBL] [Abstract][Full Text] [Related]
7. [Analysis of prognostic factors for the extent of vascularity of serous ovarian cancer on the basis of CD34 antigen expression].
Blok R; Blok K; Jeleń M; Gryboś M
Ginekol Pol; 2004 Feb; 75(2):91-8. PubMed ID: 15108579
[TBL] [Abstract][Full Text] [Related]
8. Identification of novel candidate plasma metabolite biomarkers for distinguishing serous ovarian carcinoma and benign serous ovarian tumors.
Buas MF; Gu H; Djukovic D; Zhu J; Drescher CW; Urban N; Raftery D; Li CI
Gynecol Oncol; 2016 Jan; 140(1):138-44. PubMed ID: 26521694
[TBL] [Abstract][Full Text] [Related]
9. [Relationship between interleukin-10 level in ascites of patients with primary ovarian epithelial carcinoma and immune defect in peritoneal cavity].
Zhou JW; Cheng Q; Xie X; Chen HZ; Ye DF; Lu WG
Ai Zheng; 2004 May; 23(5):573-6. PubMed ID: 15142457
[TBL] [Abstract][Full Text] [Related]
10. Increased serum 72 KDa metalloproteinase in serous ovarian tumors: comparison with CA 125.
Garzetti GG; Ciavattini A; Lucarini G; Goteri G; Romanini C; Biagini G
Anticancer Res; 1996; 16(4A):2123-7. PubMed ID: 8712754
[TBL] [Abstract][Full Text] [Related]
11. Serum CD95L Level Correlates with Tumor Immune Infiltration and Is a Positive Prognostic Marker for Advanced High-Grade Serous Ovarian Cancer.
De La Motte Rouge T; Corné J; Cauchois A; Le Boulch M; Poupon C; Henno S; Rioux-Leclercq N; Le Pabic E; Laviolle B; Catros V; Levêque J; Fautrel A; Le Gallo M; Legembre P; Lavoué V
Mol Cancer Res; 2019 Dec; 17(12):2537-2548. PubMed ID: 31537619
[TBL] [Abstract][Full Text] [Related]
12. The immune complex p53 protein/anti-p53 autoantibodies in the pathogenesis of ovarian serous carcinoma.
Mielczarek-Palacz A; Sikora J; Kondera-Anasz Z; Smycz-Kubańska M; Englisz A; Strzelczyk J; Kabut J
Ginekol Pol; 2020; 91(9):519-253. PubMed ID: 33030731
[TBL] [Abstract][Full Text] [Related]
13. [Diagnostic value of combining detection of human epididymis protein 4 and CA125 in patients with malignant ovarian carcinoma].
Wang MJ; Qi J; Wang H; Li XX; Wei BJ; Fu C; Gao J; Han BB
Zhonghua Zhong Liu Za Zhi; 2011 Jul; 33(7):540-3. PubMed ID: 22093635
[TBL] [Abstract][Full Text] [Related]
14. Autoantibody biomarkers for the detection of serous ovarian cancer.
Katchman BA; Chowell D; Wallstrom G; Vitonis AF; LaBaer J; Cramer DW; Anderson KS
Gynecol Oncol; 2017 Jul; 146(1):129-136. PubMed ID: 28427776
[TBL] [Abstract][Full Text] [Related]
15. In rheumatoid arthritis soluble CD30 ligand is present at high levels and induces apoptosis of CD30(+)T cells.
Tinazzi E; Barbieri A; Rigo A; Patuzzo G; Beri R; Gerli R; Argentino G; Puccetti A; Lunardi C
Immunol Lett; 2014 Oct; 161(2):236-40. PubMed ID: 24447865
[TBL] [Abstract][Full Text] [Related]
16. Clinical implication of serum sIL-2R levels in ovarian cancer.
Wang S; Cai G; Lu Y
J Tongji Med Univ; 1998; 18(2):126-8. PubMed ID: 10806842
[TBL] [Abstract][Full Text] [Related]
17. Selenium-Binding Protein 1 (SBP1) autoantibodies in ovarian disorders and ovarian cancer.
Yu-Rice Y; Edassery SL; Urban N; Hellstrom I; Hellstrom KE; Deng Y; Li Y; Luborsky JL
Reproduction; 2017 Mar; 153(3):277-284. PubMed ID: 27965399
[TBL] [Abstract][Full Text] [Related]
18. p53 autoantibodies as potential detection and prognostic biomarkers in serous ovarian cancer.
Anderson KS; Wong J; Vitonis A; Crum CP; Sluss PM; Labaer J; Cramer D
Cancer Epidemiol Biomarkers Prev; 2010 Mar; 19(3):859-68. PubMed ID: 20200435
[TBL] [Abstract][Full Text] [Related]
19. Significance of serum and peritoneal fluid lactate dehydrogenase levels in ovarian cancer.
Boran N; Kayikçioğlu F; Yalvaç S; Tulunay G; Ekinci U; Köse MF
Gynecol Obstet Invest; 2000; 49(4):272-4. PubMed ID: 10828712
[TBL] [Abstract][Full Text] [Related]
20. [Value of transvaginal color Doppler flow imaging conjugated with multiple serum tumor markers in diagnosis of ovarian tumors].
Wang Y; Liu LZ; Zhou JH; Pei XQ; Chen XY
Ai Zheng; 2004 Nov; 23(11 Suppl):1585-8. PubMed ID: 15566685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
